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ABSTRACT
Background: Hyperprolactinaemia is a real challenge for gynecologist and
endocrinologists ,bromocriptine was used for treating hyperprolactinaemia
,bromocriptine associated with many side effect this study aimed to compare
clinical response , side effects and tolerability of vaginal bromocriptine tablets
and suppositories versus oral bromocriptine tablets for treatment of
hyperprolactinemia
Patients and methods: Non randomized controlled clinical trial at the outpatient Clinic of Obstetrics and Gynecology,Zagazig University and Zifta
general hospital (ministry of health). This study included 87 patients who
suffered hyperprolactinaemia .Patients divided into 3 groups:Group A included
29 patients who used bromocriptine 2.5mg tablets vaginally once daily for one
month .Group B included 29 patients who administrated bromocriptine 2.5mg
vaginal suppositories once daily for one month. Group C included 29 patients
who received bromocriptine 2.5mg tablets orally twice daily for one
month.Serum prolactin was measured before and after therapy in all cases. The
work has been carried out in accordance with (The Code of Ethics of
world Medical Association) for studies involving human.
Results:Bromocriptine was effective in decreasing level of prolactin whether
used orally or vaginally. Vaginal bromocriptine suppositories application was
associated with minimal side effect both local and general .Nausea was the
most frequent side effect with oral tablets ,while excessive vaginal discharge
and dyspareunia was the most occurring local side effect. Most side effect in
three groups occur within the first 10 day after starting therapy.
Conclusions: Bromocriptine is a very effective drug in treating
hyperprolactinaemia, restoration of normal ovulation ,improvement of
mastalgia and galactorrhea ,there was a significant difference between the
three studied group regarding degree of side effect and type of side effect
occurred .Based on our results vaginal bromocriptine suppositories
(bromotaemia) is associated with minimal local and systemic side effect when
compared with bromocriptine tablets (lactodel) when used orally or vaginally.
Key words: Hyperprolactinaemia ,Bromocriptine, oral, vagina.

INTRODUCTION
yperprolactinemia is a very common
disorder, especially among female during
reproductive bearing period, affecting about
one-third of infertile women in the
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world.Prevalence of hyperprolactinaemia in
female with infertility is 33.3% in
Egypt.[1].Hyperprolactinaemia is one of the
most known challenge for
gynecologist,
andrologist,endocrinologist
and
also
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neurosurgeons.[2].Diagnosis
of
hyperprolactinemia is established when serum
level of prolactin hormone is found on 2
separate occasions to be above the high limit
of the known established range for the
population (usually 20_25ng/ml) or when the
prolactin level is increased once in addition to
symptoms
suggestive
of
hyperprolactinemia.[1]Prolactin
hormone
defined as a peptide hormone secreted from
lactotrophic cells of anterior lobe of pituitary
gland.[3 ] .Hyperprolactinaemia can be
classified into physiological as with pregnancy
and lactation, pathological as in cases with
pituitary
tumors,
drug
induced
hyperprolactinaemia like anti-depressant and
also secondary hyperprolactinaemia which
occurred with renal failure ,chest trauma and
liver cirrhosis.[3].Hyperprolactinemia can leads
to infertility as prolactin hormone leads to
inhibition of gonadotrophin releasing hormone
(GNRH) which leads to reduction of follicle
stimulating hormone (FSH)and luteinizing
hormone (LH),so leads to gonadotrophic
insufficiency
and
anovulation.
[1]Bromocriptine is a non-selective dopamine
agonist,It binds to D1 receptors present in the
gut and D2 receptors present in the
pituitary.[4]When bromocriptine binds to
dopamine receptor it inhibits central synthesis
of Prolactin .[5] Bromocriptine has many side
effect ,the most common of these are nausea,
headache and dizziness.[6]To overcome the
side effect with bromocriptine and to treat
patients who don’t tolerate or resistant to
bromocriptine
change the route of drug
administration to vaginal or other preparation
can be used as quinagolide or cabergoline. [7].
Aim of the study : the aim of this study was
to increase patients tolerance toward
bromocriptine.
PATIENTS AND METHODS
After obtaining approval from Research Ethics
Committee of Zagazig university This non
randomized controlled clinical trial was carried
out in out-patient Clinic of Obstetrics and
Gynecology,Faculty of Medicine ,Zagazig
Anwer E., et al
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University from January 2018 to January 2019
. This study included 87 patients who suffered
hyperprolactinaemia , With prolactin level
more than 20ng/ml.
''Written informed consent'' was obtained
from each participant before the beginning of
this study . Clients of age group (19 -37) years
were included in this study suffered from
Galactorrhea one of the associated symptoms
with
hyperprolactinaemia
(Infertility,
,mastalgia, amenorrhea, hypo menorrhea,
menorrhagia,
dysmenorrhea,
,recurrent
pregnancy loss and non –use of any prolactin
normalizing drug before entering the study for
at least one month. Included patients had high
pretreatment level of serum prolactin
.Exclusion criteria include breast feeder,
Pregnant, patients Suffer from symptoms
suggesting pituitary problem (visual and
occulo-motor disorders),
women Suffer
hypersensitivity or contraindicated to take
bromocriptine as uncontrolled blood pressure.
Patients divided into 3 groups: Group A
included 29 patients who used bromocriptine
2.5mg tablets vaginally once daily for one
month ,Group B included 29 patients who
administrated bromocriptine 2.5mg vaginal
suppositories once daily for one month, Group
C included
29 patients who received
bromocriptine 2.5mg tablets orally twice daily
for one month.
Complete medical history was documented ,
breast examination was done to all patients
participate in the study, Participants was
examined sitting and leaning forward .We
examined breast from the base toward the
nipple , also gentle examination of area around
the nipple. Laboratory investigation include
measuring. serum prolactin level before and
after treatment in all case by (Cobas 8000) .
Cobas 8000 is a device used in laboratory of
Zagazig university for measurement of
serum prolactin , by which immunoassay
for the in vitro quantative determination of
prolactin in human serum and plasma.
Patients were instructed to avoid touching
nipples to avoid extra elevation of serum
335 | P a g e
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prolactin. Participants were informed to report
any side effect with treatment ( nausea,
vomiting, dizziness, fainting, headache ,fatigue,
vaginal itching) And also to report degree of
side effect if this side effect was tolerable or
not. After completing the course of treatment
were asked about stoppage of breast secretion,
improvement of mastalgia ,regularity of
menstrual
cycle,
improvement
of
dysmenorrhea.
Statistical analysis Data collected throughout
history, basic clinical examination, laboratory
investigations and outcome measures coded,
entered and analyzed using Microsoft Excel
software. Data were then imported into
Statistical Package for the Social Sciences
(SPSS version 20.0) (Statistical Package for the
Social Sciences) software for analysis.
According to the type of data qualitative
represent as number and percentage ,
quantitative continues group represent by mean
± SD , the following tests were used to test
differences for significance;. difference and
association of qualitative variable by Chi square
test (X2) . Differences between paired data by
paired t, multiple by ANOVA, . P value was set
at <0.05 for significant results & <0.001 for
high significant result.Data were collected and
submitted to statistical analysis.
RESULTS
The characteristics of patients in term of age
and
BMI was analysed and show no
statistically
significant difference among
groups regarding age and BMI shown in
table(1).
There was no statistically significant difference
between the three
groups regard
main
presenting symptoms (p> 0.05), as in table (2) .
Pre treatment level of serum prolactin was high
in all patients and show significant decrease
after receiving therapy in all three groups (P
value <0.001).
There was no significant difference among
groups regarding Prolactin level before or
after therapy as shown in table (3).
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On studying the side effects appeared with the
different methods of treatment ,we found that
excessive Vaginal discharge &/or dyspareunia
is the most common side effect appeared in
group (A) 13patients(44.8%). In group (B) the
most common side effect is excessive Vaginal
discharge &/or dyspareunia which appeared in
7 patients (24.1%). In group (C) the most
frequent side effects are nausea and dizziness
with the same percentage (44.8%) . Side effects
associated significantly more in group C then A
and least at B.as shown in table (4)
We found that most side effect in three groups
occur within the first 10 day after starting
therapy. There was no significant difference
among groups regard time of appearance of
side effects as shown in table (5).Some patients
suffered side effects continued till the end of
the course of therapy with no significant
difference among the three studied groups.
According to the severity of side effect ,we
divided side effect into two goups
mild : means patients can tolerate side effect
and continued the course of treatment
sever degree : patients cannot tolerate side
effect which leads to drug discontinuation
Sever degree of side effect significantly
associated with group C as shown in table
N.(6).
There was no significant difference among
studied groups, According to effectiveness of
bromocriptine with the three different routes of
its administration as shown in table (7) When
rebound breast secretion was studied and
analysed There was no significant difference or
association among studied groups as shown in
table (7).Rebound breast secretion after one
month after we exclude pregnancy ,any factor
that leads to increase prolactin level as breast
stimulation , stress , taking any drug which has
anti-dopaminergic effect and also we exclude
all causes which leads to hyperprolactinaemia.
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Table (1) Age and BMI distribution among three studied groups
Group A
Group B
Group C
Vaginal lactodel
bromotaemia Oral lactodel
Age 27.48±4.51
26.51±4.25
27.62±4.47
BMI 29.37±4.42
28.51±3.99
28.8±4.1

Table (2) Main Complaint distribution among studied groups
A
B
C
Main complaint
N (29)
N(29)
N(29)
1ry an-ovulatory
7 (24.1%)
5 (17.2%)
4 (13.7%)
infertility
2ry an-ovulatory
9 (31.0%)
8 (27.6%)
7 (24.1%)
infertility
Amenorrhea
0 (0.0%)
0 (0.0%)
2 (6.9%)
Dysmenorrhea
1 (3.4%)
0 (0.0%)
0 (0.0%)
Irregular menses
Galactorrhea
Mastalgia

2 (6.9%)
9(31.0%)
1 (3.4%)

1 (3.4%)
13(44.8%)
2 (6.9%)

P
0.586
0.727

P value

0.41

2 (6.9%)
12(41.45)
2 (6.9%)

Table (3) Serum Prolactin level (ng/ml)between the three studied groups before and after using drug
Group A
Group B
Group C
P Value
Before
32.08±9.69 29.96±8.92
29.64±10.04
0.578
treatment
After
16.15±6.82 14.25±5.2
15.66±6.8
0.723
treatment
P value
.0..0
.0..0
.0..0
Table (4) Side effect distribution among three studied groups
Side effect
Group A
Group B
Group C
Nausea
11 (37.9%)
6(20.7%)
13 (44.8%)
Vomiting
6 (20.7%)
3 (10.3%)
6 (20.7%)
Dizziness
8 (27.6%)
3 (10.3%)
13 (44.8%)
Fainting
0 (0.0%)
0 (0.0%)
3 (10.3%)
Headache
9 (31.0%)
3(10.3%)
10 (34.5%)
Fatigue
8 (27.6%)
0 (0.0%)
9 (31.0%)
Excessive
13 (44.8%)
7 (24.1%)
0 (0.0%)
Vaginal
discharge
Anwer E., et al
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P Value
0.13
0.48
0.013*
0.045*
0.073
0.001*
0.001*
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&/or dyspareunia

Table (5) Timing of adverse effect among studied group.
Group A
Group B
During first 10 day of treatment
16 (55.2%)
13 (44.8%)
Lasting more than 10 day of treatment 3 (10.3%)
5 (17.2%)
P Value >0.05 is non _significant.

Group C
22 (75.9%)
9 (31.0%)

Table (6) Degree(intensity) of side effects among studied groups
Degree of side effect
Group A
Group B

Group C

No side effect appeared
Mild
Sever

4 (13.8%)
18 (62.1%)
7 (24.1%)

12(41.4%)
13 (44.8%)
4 (13.8%)

16 (55.2%)
12 (41.4%)
1 (3.4%)

P Value
0.051
0.12

P
Value
0.012*

Table (7)Effectiveness of drug among studied groups (out come)
Effectiveness of drug
Group A
Group B

Group C

P Value

Stoppage of galactorrhea

20 (69.0%)

13 (44.8%)

0.094

Improvement of mastalgia

12 (41.4%)

11 (37.9%)

0.54

Regaining normal ovulation

12 (41.4%)

14 (48.3%)

0.83

Restoring regular menstrual bleeding

7 (24.1%)

14 (48.3%)

0.12

Improvement of dysmenorrhea

4 (13.8%)

20
(69.0%)
15
(51.7%)
14
(48.3%)
13
(44.8%)
2 (6.9%)

3 (10.3%)

0.68

Rebound breast secretion

10(34.5%)

9(31.0%)

6(20.7%)

.0.0

DISSCUSION
In this clinical trail we aim to increase patients
tolerance toward bromocriptine ,we studied on
87 patients in child pearing period with
hyperprolactinaemia.
patients participate in the current study
were divided into three groups.
first group received bromocriptine
mesylate tablets vaginally.
Anwer E., et al
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Second group received bromocriptine
mesylate suppository vaginally.
Third group received bromocriptine
mesylate tablets orally.
(Darwish et al)[7] compare between
bromocriptine orally , vaginally and rectally in
treating hyperprolactinaemia, and in another
study they compared the superiority of vaginal
suppositories over bromocriptine tablets when
338 | P a g e
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taken
vaginally
in
treating
hyperprolactinaemia.
(Kletzky and vermesh )[13] studied the
effectiveness of vaginal bromocriptine tablets
in treating women with hyperprolactinaemia.
(Katz et al)[15] compared the circulating level
of bromocriptine after vaginal compared to oral
administration.
Firstly,the three studied groups show no
statistically significant difference as regard
patients characteristics (age , BMI ) as shown in
In table (1)
These finding running in agreement with
(Darwish et al)[11] ,in this report researchers
conducted a study to compare effectiveness
and side effect tolerability of bromocriptine
when taken orally , vaginally and rectally ,in
their randomized study performed on 69, the
patients of three groups didn’t show any
statistically significant difference as regard
patients age and BMI.
(Kletzky and vermesh)[13] and (Katz et
al)[15] compared the effectiveness of
bromocriptine tablets when taken orally or
vaginally patients participate in this study
show no statistically significant difference as
regard age and BMI.
When main presenting symptoms distribution
among the three studied groups were studied,
there was no significant difference between the
three studied groups as shown in table(2). In
this table we found that galactorrhea was the
most frequent complain among patients
receiving
both vaginal bromocriptine
suppositories and oral bromocriptine tablets
(44.8%)
and
(41.4%)
respectively,this
percentage was greater than percentage of
galactorrhea among patient receiving vaginal
bromocriptine
suppository
and
oral
bromocriptine (25%) and (22.2%) respectively
in (Darwish et al)[7].
In our study serum prolactin show significant
decrease after receiving therapy in the three
studied groups , P value with oral
bromocriptine , vaginal bromocriptine tablets
and vaginal bromocriptine suppository was
<0.001 as show in table (3).
Anwer E., et al
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This result was in agreement with that of
(Motazedian et al)[10]and (Alhusaynei et
al)[14], these studies show a significant
decrease in serum prolactin level after
bromocriptine administration either orally or
vaginally with P value <0.001 in both study .
Results in table (3) was in contrast to (Kletzky
and vermesh)[13] and (Darwish et al)[7] the
first
study the effectiveness of vaginal
bromocriptine tablets in treating women with
hyperprolactinaemia they found that daily
vaginal dose of 2.5mg of bromocriptine leads
more reduction in serum prolactin when
compared with oral tablets.
(Darwish et al)[7] observed that vaginal
bromocriptine suppositories more effectiveness
than vaginal bromocriptine tablets in lowering
level of serum prolactin this result disagree
with our result which proved that no significant
difference among studied group P value
>0.05.This can be explained by in our study
vaginal tablet was soaked with water before
insertion this can increase drug absorption.
Regarding Side effects studied among the three
studied groups , side effects
associated
significantly more in group C ( oral
bromocriptine )then A (vaginal bromocriptine
tablets )and least at B (vaginal bromocriptine
suppository ) as shown in table (4).
According to side effect that occurred with each
line of treatment , in this study we found that
nausea and dizziness were the most common
occurring side effect among patients receiving
oral bromocriptine 13 cases (44.8%) as shown
in table (4).This result in agreement with
(Kahnamuie and Asadzadel ) [2],(Nirhale et
al)[16] , (Motazedian et al)[10] ,(Darwish et
al)[7], (Cho et al)[17] in the all previous
mentioned studies they observed that nausea
was the most common occurring side effects
among patients receiving oral bromocriptine
tablets but with different percentage (39.9%) ,
(50%) , (43.6%) ,(70.4%) , (23%) respectively .
In table (4), the most frequent side effect
among cases receiving vaginal bromocriptine
tablets was excessive vaginal discharge
/dysparaunea 13 case (44.8%). This result in
339 | P a g e
6

Mostafa et al.: Clinical response and patient's tolerance of vaginal versus oral

March. 2021 Volume 27 Issue 2

disagree with (Katz et al)[15] they compare
oral and vaginal bromocriptine tablets and
observed no difference in side effects between
both groups as only one case in each group
suffer nausea and dizziness.
Also results regarding side effects with vaginal
tablets
disagree with (Kletzky and
vermesh)[13]
they found that 1 (10%)
receiving vaginal
bromocriptine tablets
suffered conistipation.
When side effects with vaginal bromocriptine
suppositories were studied excessive vaginal
discharge /dysparaunea was the most occurring
side effect 7 cases (27.1%).
This result was in agreement with (Darwish et
al)[7]
they studied the effectiveness of
bromocriptine by its application with different
route oral tablets 2.5mg , vaginal suppository
5mg and rectal suppository 5mg for one month
, they observed that excessive vaginal discharge
was the most frequent one occurring among
patients
receive
vaginal
bromocriptine
suppositories 8 cases (40%) .
When timing of adverse effect was studied
among the three studied groups , We found that
most side effect in three groups occur within
the first 10 day after starting therapy. There was
no significant difference among groups regard
time of appearance of side effects as shown in
table (5).
This result was in agreement with (Kletzky
and vermesh)[13] they reported that side effect
with oral bromocriptine administration was
recorded in the first 2 week of treatment.
In table (6) degree of side effect was studied ,
According to the severity of side effect ,we
divided side effect into two goups :
1- mild : means patients can tolerate side effect
and continued the coarse of treatment.
2-sever degree : patients cannot tolerate side
effect which leads to drug discontinuation .
Sever degree of side effect significantly
associated with group C(oral bromocriptine)
7cases (24.1%). This results was in agreement
with (Nirhale et al)[16] they studied the
effectiveness of oral bromocriptine tablets on
management of mastalgia , they reported that 3
Anwer E., et al
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cases (13.04%) suffered sever non tolerable
side effects.
(Darwish et al)[7] reported 6 patient (22.2%)
received oral bromocriptine ended with drug
discontinuation due to un-tolerable side effect.
In a study by(Kahnamuie and Asadzadel)
[2]they studied patients tolerance toward oral
bromocriptine
tablets
and
vaginal
bromocriptine suppository on 180 patients
dividied into two group each one composed of
90 cases , they reported percentage of sever
side effect with drug discontinuation (31.2%)
and (22.2%) in oral and vaginal group
respectively .
Regarding number of cases suffer side effects
that occurred among the studied groups oral
bromocriptine administration associated with
the largest number cases who suffer of side
effect 25 (86.2%) as shown in table (6). This
percentage was higher than percentage of side
effect with oral bromocriptine in astudy by
(Alhusaynei et al)[14] as they reported 55%
suffered from many side effect .
In our study when effectiveness of
bromocriptine with the three different routes of
its administration was studied , There was no
significant difference among studied groups as
shown in table ( 7 ).
Stoppage of galactorrhea in patient receiving
oral bromocriptine
occurred in 13 cases
(44.8%) , this percentage found to be less than
that occurred in a study (Arduc et al) [18]who
studied the effectiveness of oral bromocriptine
in treatment of hyperprolactinaemia and
reported (79%) stoppage of galactorrhea , we
suggest that difference due to prolonged
duration of therapy (17.8+_6.0 months)
compared with one month treatment of our
study.
(Moatazedian et al)[10]
studied oral
bromocriptine administration and fertility
outcome on 94 patients received 2.5mg oral
bromocriptine for one month ,they observed
galactorrhea was improved in (51.1%) this
percentage higher than that reported in our
study.

340 | P a g e
7

Zagazig University Medical Journal, Vol. 27 [2021], Iss. 2, Art. 15

March. 2021 Volume 27 Issue 2

(Arduc et al)[18] reported also (80%) of
patients suffered irregularity of menstrual cycle
were improved and restored normal regular
menstrual bleeding , this percentage found to
be higher than our results as we reported
(48.3%) restoring of regular menstrual
bleeding. This result can be due to increased
duration of treatment in (Arduc et al)[18]
(17.8+_6.0 months) versus one month of our
study.
Restoration of normal regular menstrual
bleeding with oral bromocriptine occurred in
(48.3%) this result found to be higher than that
reported by (Moatazedian et al)[10] they
reported (33%) .
According
to
effectiveness
of
oral
bromocriptine in treatment of mastalgia , we
found that 11 patients(37.4%) show
improvement of mastalgia as shown in table
(7).This percentage is less than that found in
(Nirhale et al)[16] who found (56.9%)
improvement of mastalgia this difference can
be due to prolonged duration of therapy.
(Alhusaynei et al)[14] studied effect of oral
bromocriptine
in
women
with
hyperprolactinaemic
amenorrhea , oral
bromocriptine tablets 2.5mg twice daily for 8
weeks , they reported (78.6%) with stoppage
of galactorrhea
and (69.23%) with
normalization of menstrual bleeding , Both
results higher than our results this difference
can be explained due to prolonged period of
treatment.
When effectiveness of vaginal bromocriptine
tablets was studied we found that stoppage of
galactorrhea
occurred
in
20(69.0%),
improvement of mastalgia
and regaining
normal ovulation occurred in 12 (41.4%) ,
restoring regular menstrual bleeding occurred
in 7 (24.1%) , as shown in table (7).
In our study as shown in table (7) vaginal
bromocriptine tablets and suppositories equally
associated with (69.0%) stoppage of
galactorrhea.
In table (7), which demonstrate rebound breast
secretion after one month coarse of therapy in
the three studied groups we found that there
Anwer E., et al
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was no significant difference or association
among studied groups .Rebound breast
secretion after one month after we exclude
pregnancy ,any factor that leads to increase
prolactin level as breast stimulation , stress ,
taking any drug which has anti-dopaminergic
effect and also we exclude all causes which
leads to hyperprolactinaemia.
CONCLUSION
It could be concluded from this study that
bromocriptine is a very effective drug in
treating hyperprolactinaemia, restoration of
normal ovulation ,improvement of mastalgia
and galactorrhea ,there was a significant
difference between the three studied group
regarding degree of side effect and type of side
effect occurred .Based on our results vaginal
bromocriptine suppositories is associated with
minimal local and systemic side effect when
compared with bromocriptine tablets when used
orally or vaginally.
No conflict of Interest .
No financial disclosures .
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